Clobetasone Butyrate 0.05% Cream and Ointment (Eumovate®) is a moderately potent topical corticosteroid. Clinical experience shows that moderate strength topical corticosteroids act more quickly than hydrocrtisone and as a result can reduce the total amount of drug that is used.
- Topical corticosteroid efficacy has been repeatedly demonstrated in randomised controlled trials for atopic eczema.
- Eumovate® has been shown to be more effective than hydrocortisone 1.0% for treating atopic eczema, and skin thinning has not been reported with short term use. There was negligible systemic absorption.
- Eumovate® has recently been approved for short term use in adults and children over 12 who have acute eczema and allergic dermatitis directly from their local pharmacist in the UK.
[J Dermatol Treat. 2003 Jun;14(2):71-85.]
- Clobetasone butyrate (Eumovate®) is significantly different from, and should not be confused with clobetasol propionate (Dermovate®), which is classed as a very potent corticosteroid.
- Topical corticosteroids are indicated to provide symptomatic relief of inflammation and/or pruritus associated with acute and chronic corticosteroid-responsive disorders.
- The location of the skin lesion to be treated should be considered in selecting a formulation. Weak to moderate potency products may be used on the ears, trunk, arms, legs and scalp. They should be used on the face and intertriginous areas for a limited duration.
- In dermatological practice, hydrocortisone 1% remains a mainstay for treatment of facial eczema and skin folds, but is often not effective for treating eczema affecting other body areas.
These terms can be used interchangeably when referring to the potency of a topical corticosteroid:
Weak/Mild = Low
Moderate = Medium
Potent = High
Very Potent = Superpotent